-First Post While the average Human Development Index (HDI) for the region is 0.558, below the world average of 0.693, South Asia saw the highest growth in the index between 2000 and 2012, according to the United Nations Human Development Report 2013. The region registered an annual growth of 1.43 percent in HDI, the highest compared to other regions. It also said that the developing countries as a whole are driving the...

-The Hindu Justice Prabha Sridevan’s judgment permitting the production and sale of a generic version of a cancer drug is a victory for patients. It posits the public interest, especially in matters of health care, right at the heart of intellectual property rights in India Monday was a remarkable day for cancer patients in India. To them, the country said — “we care.” I am talking about the astounding decision by Justice...

-Live Mint Govt reiterates it will crack down hard on tax evaders, defends steps introduced in Finance Bill to check evasion The government on Tuesday reiterated its intention to crack down hard on tax evaders and defended some of the stringent provisions introduced in the Finance Bill last week to check evasion, including granting wider powers of arrest to taxmen and making certain offences non-bailable. Finance minister P. Chidambaram, in his budget speech...

-The Hindu Bayer's plea dismissed by the Intellectual Property Appellate Board The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs. Disposing an appeal filed by Bayer...

-The Business Standard Chennai: The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India. IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to...